Secobarbital (marketed under the brand names Seconal® and Tuinal) is a drug which is a barbiturate derivative. It possesses anaesthetic, anticonvulsant, sedative and hypnotic properties. Was previously known as quinalbarbitone in the UK (former BAN).
Indications
Secobarbital is indicated for:
- Treatment of epilepsy
- Temporary treatment of insomnia in patients habituated to barbiturates
- Use as a preoperative medication to produce anaesthesia and anxiolysis in short surgical, diagnostic, or therapeutic procedures which are minimally painful.
Availability
It is available as either a free
acid or a
sodium salt. The free acid is a white
amorphous powder that is slightly soluble in water and very soluble in ethanol. The salt is a white
hygroscopic powder that is soluble in water and ethanol.
Secobarbital sodium
The sodium salt of secobarbital is classified separately from the free acid, as follows:
- CAS number: 309-43-3
- Chemical formula: C12H18N2NaO3
- Molecular weight: 260.265
Side effects
Side effects of secobarbital include:
Withdrawal
Secobarbital is a fairly
addictive drug, and
withdrawal symptoms can occur when if long-term usage is abruptly ended. Withdrawal symptoms can include:
- Insomnia
- REM rebound
- Anxiety
- Tremors
- Seizures
- Lack of appetite
Recreational use
Secobarbital began to be widely abused in the
1960s and
1970s, although with the advent of
benzodiazepines, they have become less commonly used.
Secobarbital has acquired many nicknames, the most common being "reds" (it was originally packaged in red capsules). Another common nickname is "seccies". A less common nickname is "dolls"; this was partly responsible for the title of Jacqueline Susann's novel Valley of the Dolls, whose main characters use secobarbital and other such drugs.
Another popular brand of barbiturate pill Tuinal contained a combination of secobarbital and amobarbital but is now rarely prescribed due to problems with abuse and overdose.
Secobarbital overdose was the most common method of implementing
physician-assisted suicide (PAS) in Oregon until
Eli Lilly and Company discontinued manufacturing it in May 2001, leading to a shortage of the drug. Since then,
pentobarbital has dominated in Oregon PAS.
Ranbaxy Laboratories Limited have experienced approval issues in their attempts to produce secobarbital, but the shortage is expected to end in January 2006.
External links
Anesthetics | Barbiturates | Sedatives
Secobarbital | Secobarbital